Premium
TOPICAL MINOXIDIL THERAPY FOR ANDROGENIC ALOPECIA IN THE MIDDLE EAST
Author(s) -
KARAM PAULA
Publication year - 1993
Publication title -
international journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 93
eISSN - 1365-4632
pISSN - 0011-9059
DOI - 10.1111/j.1365-4362.1993.tb02756.x
Subject(s) - medicine , minoxidil , male pattern baldness , dermatology , hair growth , hair loss , surgery , physiology , scalp
Background . A 48‐week open label trial was conducted in five Middle‐Eastern countries (Lebanon, Egypt, Saudi Arabia, Jordan, and the United Arab Emirates) to determine the safety and efficacy of 2% minoxidil in the treatment of early androgenic alopecia and to compare the response with Western countries. Methods . One hundred and ninety‐five men aged between 19 and 47 years were enrolled. The duration of their baldness varied from 6 months to 10 years, and they all showed a type III vertex or type IV of the modified Hamilton scale. Baldness pattern, diameter of the balding area, hair counting within a 2.5 cm bald patch as well as investigator's and patient's evaluation were regularly noted. Results . No significant changes were observed in vital signs or laboratory parameters. Of the 161 patients considered evaluable at 48 weeks, 80% showed moderate to dense growth. The mean increase in nonvellus hair at 12 months was 234. Conclusions . The age of the patient and the type of baldness rather than its duration affected the final outcome.